Tumor-bearing mice were divided into monotherapy treatment groups to receive 200 μg injections of anti-PD-1, anti-LAG-3, or anti-TIM-3 mAbs, or IgG isotype control. This evidence concerns the gene PDCD1 and neoplasm.